Study of people with FSHD1 gene changes
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This is a study that follows people who have a confirmed FSHD1 genetic change (and some healthy people for comparison). It may help researchers better understand the condition and how it affects people over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have FSHD1 genetic confirmation by a specific lab test (PFGE-based Southern blot)
- You can be any age and can have symptoms or not
- You must be willing to participate in the study
- You should not have another muscle/nerve disease (for example, limb-girdle muscular dystrophy or myotonic dystrophy)
- You should not have a serious major illness such as significant heart, liver, or kidney disease, or a major mental illness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medicine called Del-brax (AOC 1020) for people with facioscapulohumeral muscular dystrophy (FSHD). The goal is to see if it can help improve muscle strength and slow the disease. You may be able to join if you have a confirmed FSHD diagnosis and can walk at least 10 meters on your own.
This study follows people with myotonic dystrophy type 1 over time to learn more about the condition. It is for people of any age who have genetic confirmation of DM1, whether or not they have symptoms.
This trial studies how well certain physical/movement tests work in people with facioscapulohumeral muscular dystrophy (FSHD). It may help clinicians measure changes more accurately and tailor care over time.
This study looks at muscle MRI images and walking patterns (3D gait analysis) in people with FSHD. It helps researchers understand how the disease affects movement and muscle over time.
This study follows people with FSHD2 over 18 months to learn how the disease progresses and affects daily life. No new drugs are tested—just regular check-ups and an MRI scan.
This study follows FSHD patients for 10 years to see how the disease progresses. It includes people who were in earlier FSHD studies and some new patients with genetic confirmation of FSHD.
Hear when a new Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.